New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2012
05:13 EDTDECK, ZNGA, AMRC, ZIP, BAC, HD, DNDN, GLD, WFMI, LOW, EXC, SBUX, CL, SIRI, PM, NLY, AGNC, CMI, PCAR, REGN, PFE, KO, MSFT, YHOO, AAPL, IBM, PCYC, JPM, MNST, HSTM, CONN, SXCI, QCOR, IDIX, VVUS, MDVN, PCLN, GS, ACATJim Cramer's "Mad Money"
Wednesday was Jim Cramer's anniversary of his "Mad Money" TV show. He said it's time to come off the sidelines, sell those bank CDs earning 0.4% interest and invest in great American companies. Cramer said today's markets are being driven by pure growth, U.S. growth. He said everything from health care to retail to technology, even the homebuilders, are just beginning to show sustainable recoveries. Stocks like JPMorgan Chase (JPM) and IBM (IBM), are both leading the charge. Then there's Apple (AAPL) Cramer said while some investors can't fathom Apple's historic rise, he remembers a time when Coca-Cola (KO) and Pfizer (PFE) were the most valued companies on Wall Street. Apple is so much more than just a technology company, he said, adding it's a communications, education and entertainment company as well, all of which makes it worth its valuation. Cramers said the markets can most certainly take out its recent highs and march into bull-market mode, with a pickup in commercial construction and improved job growth looming just around the corner. Cramer recapped his "Magnificent Seven" speculative stocks to show viewers just how lucrative this under-rated method of investing can be. He said that every investor should have one spot in their portfolio dedicated to a speculative stock that adds excitement to their holdings. Cramer's magnificent seven stocks included Pharmacyclics (PCYC), a stock up 393% over the past 12 months, Medivation (MDVN), a biotech up 320%, Idenix Pharmaceuticals (IDIX), up 277%, and Vivus (VVUS), up 224%. Rounding out the seven were Arctic Cat (ACAT), which has risen 204% in 12 months, Conn's (CONN), up 211% and HealthStream (HSTM), which is up 192%. Next, Cramer also highlighted the seven best stocks that he's recommended since "Mad Money" first aired back in 2005, a list that exemplifies what "staying in the game" is all about. His top seven recommendations included Monster Beverage (MNST), which has risen 1,600% over the past seven years, the biotech company Regeneron (REGN), up 1,700% over seven years and Medivation (MDVN), the only company to make both of Cramer's lists, up 1,800%. The list also included Green Mountain Coffee Roasters (GMCR), a stock that despite huge losses recently, is still up 2,700% over seven years, SXC Health Solutions (SXCI) up 2800%, travel site Priceline.com (PCLN), up 2,850% and finally, Questcor Pharmceuticals (QCOR), which has rallied an astounding 7,066% over seven years. Cramer said when companies are riding long-term trends, their successes can turn into huge gains for shareholders. Next, Cramer responded to a New York Times op-ed piece chastising Goldman Sachs (GS), saying that the company often put its own interests ahead of those of its clients. Cramer said he didn't see any of this type of behavior when he worked for Goldman years ago. He said while he's sure that many of Goldman's employees are still committed to doing right by clients, perhaps this article can serve as a wake-up call for the firm to do even better for its clients, even if that means being less profitable in the short term. MAD TWEETS: Cramer said that Microsoft (MSFT) was a good stock, Yahoo (YHOO) was a bad one and Sirius XM Radio (SIRI) was a speculative one. Deckers Outdoor (DECK), said the warm winter hit this cold-weather shoemaker hard. Cramer was bullish on Starbucks (SBUX). Restructuring is working at Lowes (LOW) but he still prefers Home Depot (HD), and with gold stocks still suffering, he still likes the SPDR Gold Shares (GLD). Finally when asked about ZipCar (ZIP), Cramer said if investors want to invest in a recent IPO, he'd go with mobile game maker Zynga (ZNGA). LIGHTNING ROUND: (Bullish) ECL;PM; PCAR; CMI; AGNC; NLY; AMRC; EXC; WFMI. (Bearish) DNDN; BAC. Reference Link
News For DECK;SIRI;NLY;AGNC;YHOO;MSFT;CMI;GS;PCLN;PCAR;QCOR;SXCI;PM;REGN;MNST;CL;HSTM;CONN;ZNGA;ACAT;IDIX;ZIP;VVUS;MDVN;BAC;HD;JPM;PCYC;DNDN;PFE;KO;GLD;WFMI;AAPL;IBM;LOW;EXC;SBUX;AMRC From The Last 14 Days
Check below for free stories on DECK;SIRI;NLY;AGNC;YHOO;MSFT;CMI;GS;PCLN;PCAR;QCOR;SXCI;PM;REGN;MNST;CL;HSTM;CONN;ZNGA;ACAT;IDIX;ZIP;VVUS;MDVN;BAC;HD;JPM;PCYC;DNDN;PFE;KO;GLD;WFMI;AAPL;IBM;LOW;EXC;SBUX;AMRC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | all recent news | >>
April 7, 2014
08:56 EDTJPMJPMorgan, U.K.'S DFID, CDC to invest $20M combined in Novastar Ventures
Subscribe for More Information
08:45 EDTAAPLInvenSense price target raised to $27 from $20 at Pacific Crest
Subscribe for More Information
07:51 EDTAAPLApple sent iTV panel samples from Korean display maker, Korea Herald says
Subscribe for More Information
07:37 EDTAAPLApple considered dumping long-time ad agency, WSJ reports
Subscribe for More Information
07:27 EDTPFEAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTZNGAZynga added to Best Ideas List at Wedbush
Subscribe for More Information
07:16 EDTAAPLRetailers muscle into competitive mobile payment market, Reuters says
Subscribe for More Information
07:16 EDTQCORMallinckrodt and Questcor hold a joint conference call
Subscribe for More Information
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-nave, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-nave, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.
07:08 EDTQCORQuestcor to be bought by Mallinckrodt for cash, stock valued at $86.10 per share
Subscribe for More Information
07:04 EDTQCORQuestcor acquired by Mallinckrodt for $5.6B
Subscribe for More Information
06:41 EDTMSFTMicrosoft pushes for programming to rival Amazon, Netflix, Bloomberg says
Subscribe for More Information
06:36 EDTAAPLApple's sales force worried about iPhone outlook, Re/code reports
Apple's (AAPL) sales force has been worried about weakness in the iPhone's market share, amid strong competition from Google's (GOOG) Android operating system, a document presented in a court case showed, Re/code reported on Friday. According to the internal Apple document, the only portions of the smartphone market showing growth were large devices costing more than $300 or devices that cost less than $300, the website stated. Reference Link
06:28 EDTGSGoldman sees opportunity to slice China junk debt after gains, Bloomberg says
Subscribe for More Information
06:19 EDTGLDSPDR Gold Trust overall implied volatility at 15; 26-week average is 19
Subscribe for More Information
06:18 EDTMSFTMicrosoft starts developing 4th-generation Surface, DigiTimes reports
Subscribe for More Information
05:49 EDTPCLNStocks with implied volatility movement; ETFC PCLN
Subscribe for More Information
April 6, 2014
17:48 EDTAAPLGoogle set to announce Android TV, The Verge says
Subscribe for More Information
14:21 EDTYHOOYahoo plans to acquire bigger budget TV programming, WSJ says
Subscribe for More Information
13:46 EDTPFEPfizer's palbociclib significantly prolonged PFS in metastatic breast cancer
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use